Company news

Vaccinex, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study

October 7, 2026

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

July 8, 2026

Vaccinex Reports 2025 Annual Financial Results

April 29, 2026

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

December 23, 2025

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

April 21, 2025

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 7, 2025

Decks